Paper Details

  1. Home
  2. Paper Details

Effect of Futibatinib on Cardiac Repolarization: Results of a Randomized, Controlled, Double-Blind, QT/QTc, Phase 1 Study in Healthy Subjects.

Author: BenhadjiKarim A, HeYaohua, LesterRobert, MinaMark, SonnichsenDaryl, YamamiyaIkuo

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study assessed the effects of futibatinib, a fibroblast growth factor receptor (FGFR) 1-4 inhibitor, on the QTcF interval in healthy subjects. A four-period, crossover, phase 1 thorough QT/QTc study compared single doses of futibatinib at therapeutic and supratherapeutic doses to placebo and a positive control. The study found no significant prolongation of QTcF or effects on other cardiac measures at therapeutic or supratherapeutic doses, suggesting a favorable cardiac safety profile for futibatinib.
Paper Details　
Original Abstract of the Article :
Futibatinib, a fibroblast growth factor receptor (FGFR) 1-4 inhibitor, is being investigated for FGFR-aberrant tumors. A 4-period, crossover, phase 1 thorough QT/QTc study compared effects on Fridericia heart rate-corrected QT (QTcF) interval of single doses of futibatinib 20 and 80 mg (therapeutic ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/cpdd.1195

データ提供：米国国立医学図書館（NLM）

Futibatinib: A New Weapon in the Fight Against FGFR-Aberrant Tumors

FGFR-aberrant tumors, a type of cancer characterized by mutations in the fibroblast growth factor receptor (FGFR), are challenging to treat. It's like a desert stronghold, with a resilient enemy protected by a fortified wall of resistance. This study investigates the effects of futibatinib, an FGFR inhibitor, on cardiac repolarization, a crucial factor in ensuring heart rhythm stability.

Protecting the Heart's Rhythm: Futibatinib and Cardiac Repolarization

The study found that futibatinib, at both therapeutic and supratherapeutic doses, did not prolong the QTc interval, a measure of cardiac repolarization. This finding suggests that futibatinib could be a safe and effective treatment option for FGFR-aberrant tumors, without compromising cardiac function. It's like finding a way to breach the stronghold's defenses without disrupting the delicate balance of the surrounding ecosystem.

Navigating the Desert of Cancer Treatment: A Safe and Effective Approach

This research offers a promising new approach to treating FGFR-aberrant tumors, exploring the potential of futibatinib as a safe and effective therapeutic agent. The study highlights the importance of understanding the potential cardiac effects of cancer treatments, ensuring that patients receive the best possible care while minimizing the risk of complications. It's a reminder that even in the face of challenging diseases, we can find ways to navigate the desert of treatment with greater precision and safety.

Dr.Camel's Conclusion

The battle against cancer is a complex and challenging journey through a vast desert. This research explores the potential of futibatinib, a new weapon in the fight against FGFR-aberrant tumors. The study's findings offer a glimmer of hope, suggesting that this drug could be a safe and effective treatment option, potentially opening new pathways to recovery and improved quality of life. It's a reminder that even in the face of adversity, we can find new sources of strength and resilience, navigating the desert of cancer treatment with greater hope and determination.
Date :
  1. Date Completed 2023-03-02
  2. Date Revised 2023-03-21
Further Info :

Pubmed ID

36404525

DOI: Digital Object Identifier

10.1002/cpdd.1195

Related Literature

Article Analysis
・Effects of futibatinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.